Drug Eluting Stents (DES) are the mainstay of coronary artery disease treatment. Although DES design iterations have reduced MACE in the first year after PCI, beyond 1-year, a persistent 2-3% annualized event rate without plateau is observed. The DynamX™ Novolimus-Eluting Coronary Bioadaptor System is a 71 micron thin, cobalt-chromium platform with a novel "uncaging" mechanism of the circumferential rings after 6 months while maintaining axial links following uncaging.
Conventional metallic DES "cage" the coronary artery, cause geometric distortion and inhibit positive adaptive remodeling and vasomotion. These factors likely contribute to the persistent annual MACE rate after PCI. The DynamX Bioadaptor combines acute performance of contemporary DES and unique benefits of arterial "uncaging" within 6 months, with restoration of normal geometry, compliance and positive adaptive remodeling. The device was evaluated in a mechanistic clinical study which enrolled 50 patients. Multiple clinical endpoints including device/ procedure success and target lesion failure (TLF) at 6, 9 and 12 months were assessed with clinical follow-up continuing annually through 3 years. Multimodality imaging endpoint analyses using QCA and IVUS were performed at baseline and at 9 or 12 months in subgroups. OCT imaging was performed in a subset of patients at the 9 or 12 month time point. Observed an acute lumen gain of 1.63 ± 0.34 mm with low late lumen loss (0.12 ± 0.18 mm) by QCA. IVUS imaging showed the unique feature conferred by vessel uncaging which allowed for the vessel to undergo positive adaptive remodeling to maintain lumen area for good blood flow, a characteristic not observed with metallic stents. Clinical data showed no Target Vessel Revascularization (TVR) or Definite/Probable device thrombosis through 12 months. The DynamX Bioadaptor combines the acute performance of contemporary DES with the unique benefit of arterial "uncaging" to permit a return towards normal vessel function along with compensatory positive adaptive remodelling which may result in fewer clinical events beyond one year. This fundamental innovation in device design allows the bioadaptor to match current DES in acute performance while showing the promise of mitigating the 2-3% annualized event rates beyond year 1.
###
Notes to editors
Key information
- o A PCR Press Release on DynamX Bioadaptor, a novel "uncaging" platform for coronary artery revascularisation - 12-month clinical and imaging results by Stefan Verheyre
o Presentation during the #PCR e-Course - http://www.pcr-ecourse.com
o Session on Main Arena Channel, Friday 26 June - 14:08 Paris time (UTC+2)
o PCR e-Course: 25, 26, 27 June 2020
About PCR
The mission of PCR is to serve the needs of each individual patient by helping the cardiovascular community to share knowledge, experience and practice. PCR offers a wide range of other educational meetings and resources for the continuing education of the interventional cardiovascular community. These include major annual Courses across the globe, e-Learning with high-profile PCR Webinars, Courses specifically dedicated to valvular heart disease, tailor-made PCR Seminars on specific topics, online resources and medical publications such as EuroIntervention, the official journal of the EAPCI.
Gateways to all PCR activities are available on http://www.pcronline.com
For further information, please contact Célia Vilà: cvila@europa-group.com